Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study

被引：26

作者：

Woyach, Jennifer A. ^{[1
]}

Flinn, Ian W. ^{[2
]}

Awan, Farrukh T. ^{[3
]}

Eradat, Herbert ^{[4
]}

Brander, Danielle ^{[5
]}

Tees, Michael ^{[6
]}

Parikh, Sameer A. ^{[7
]}

Phillips, Tycel J. ^{[8
]}

Ghori, Razi ^{[9
]}

Reddy, Nishitha M. ^{[9
]}

Farooqui, Mohammed Z. H. ^{[9
]}

Byrd, John C. ^{[10
]}

Stephens, Deborah M. ^{[11
]}

机构：

[1] Ohio State Univ, Columbus, OH 43210 USA

[2] Sarah Cannon Res Inst, Nashville, TN USA

[3] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA

[4] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[5] Duke Univ, Duke PDC, Durham, NC USA

[6] Colorado Blood Canc Inst, Denver, CO USA

[7] Mayo Clin, Rochester, MN USA

[8] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA

[9] Merck & Co Inc, Rahway, NJ 07065 USA

[10] Univ Cincinnati, Coll Med, Cincinnati, OH USA

[11] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-163596

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：7004 / 7006

页数：3

共 13 条

[11] Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
Wierda, William G.
Shah, Nirav N.
Cheah, Chan Y.
Lewis, David
Hoffmann, Marc S.
Coombs, Catherine C.
Lamanna, Nicole
Ma, Shuo
Jagadeesh, Deepa
Munir, Talha
Wang, Yucai
Eyre, Toby A.
Rhodes, Joanna M.
McKinney, Matthew
Lech-Maranda, Ewa
Tam, Constantine S.
Jurczak, Wojciech
Izutsu, Koji
Alencar, Alvaro J.
Patel, Manish R.
Seymour, John F.
Woyach, Jennifer A.
Thompson, Philip A.
Abada, Paolo B.
Ho, Caleb
McNeely, Samuel C.
Marella, Narasimha
Nguyen, Bastien
Wang, Chunxiao
Ruppert, Amy S.
Nair, Binoj
Liu, Hui
Tsai, Donald E.
Roeker, Lindsey E.
Ghia, Paolo
LANCET HAEMATOLOGY, 2024, 11 (09): : e682 - e692
[12] A Randomized, Open-Label Phase 2 Study of the TORC 1/2 Inhibitor Sapanisertib in Relapsed/Refractory (R/R) NFE2L2 (NRF2)-Mutated and Wild-Type (WT) Squamous Non-Small Cell Lung Cancer (sqNSCLC)
Riess, J. W.
Johnson, M. L.
Gadgeel, S.
Skoulidis, F.
Sumrow, B.
Kuriakose, E.
Albert, K.
Kittrell, N.
Akella, L.
Fiji, G.
Paik, P.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E14 - E14
[13] Phase 1-2 open-label, multiple-dose, dose-escalation study to evaluate the safety and tolerability of intravenous infusion of SNS01-T, a first-in-class modulator of eukaryotic translation initiation factor 5A (eIF5A) in patients (pts) with relapsed or refractory B-cell malignancies
Craig, Michael
Bensinger, William
Siegel, David Samuel DiCapua
Van Rhee, Frits
Novitzky, Nicolas
Mcdonald, Andrew
Gutierrez, Martin
Libby, Edward N.
Thompson, John
Belton, Alice Susannah
Barranco, Charles
Taylor, Catherine
Dondero, Richard
Browne, Leslie J.
Kurman, Michael R.
Lust, John Anthony
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

← 1 2 →